secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001193125-25-146874
Event type: other_material
Sentiment:  neutral
Materiality: 0.00
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics stockholders elect three Class II directors, ratify Deloitte as auditor at 2025 annual meeting
--------------------------------------------------------------------------------

- Elected Class II directors: Rahul D. Ballal (36,870,420 for), Jake Bauer (37,250,826 for), Andrew Phillips (31,957,928 for).
- Ratified Deloitte & Touche LLP as independent auditor for FY2025 (45,392,647 for, 2,435 against, 35,215 abstain).
- Broker non-votes of 8,099,804 existed for director elections; ratification had no broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525146874/0001193125-25-146874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525146874/d80015d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-146874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer